Raymond James lowered the firm’s price target on Ventas (VTR) to $68 from $70 and keeps an Outperform rating on the shares. Skilled nursing facilities and seniors housing operators continue to recover from the impact of the pandemic, while longer-term, increasing demand from the “Silver Tsunami” of aging demographics, a strong rate and affordability outlook, and declining new supply impact should drive strong performance throughout the decade, the analyst tells investors in a research note. Raymond James believes Ventas’s leverage profile and cost of capital will continue to improve from more consistent execution, allowing management to capitalize on accretive external growth opportunities within seniors housing.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VTR:
- BMO replaces Ventas with Welltower as top healthcare REIT pick
- Ventas price target lowered to $68 from $71 at Mizuho
- Ventas comments on master lease with Brookdale Senior Living
- Ventas price target raised to $68 from $65 at Scotiabank
- Ventas 10.6M share Spot Secondary priced at $63.90
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
